TBPH
Theravance Biopharma Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +8.4% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 0 | 20.06M | $340.93M | +5 | −5 |
| Q1 2026 | 81 | 0 | 20.48M | $332.45M | +7 | −7 |
| Q4 2025 | 81 | +1 | 20.44M | $382.41M | +1 | n/a |
| Q3 2025 | 17 | 0 | 12.34M | $180.13M | +1 | −1 |
| Q2 2025 | 14 | +1 | 10.14M | $111.79M | +2 | −1 |
| Q1 2025 | 10 | +2 | 4.07M | $36.36M | +2 | n/a |
| Q4 2024 | 8 | 0 | 3.76M | $35.35M | n/a | n/a |
| Q3 2024 | 7 | -2 | 2.37M | $19.08M | n/a | −2 |
| Q2 2024 | 9 | n/a | 6.87M | $58.23M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.07M | -12.7% | $9.53M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 920.30K | +10.4% | $8.22M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 890.57K | +3.2% | $7.95M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 438.71K | +39.4% | $3.92M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 291.53K | +51.2% | $2.60M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 221.47K | New | $1.98M | 0.0% | New | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 155.43K | -21.7% | $1.39M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 60.84K | -6.1% | $544,000 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Marshall Wace ✦ | 14.91K | -77.4% | $133,154 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 11.27K | New | $100,641 | 0.0% | New | 1 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $1.98M | 0.0% |
| AQR Capital Management | $100,641 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 49.68M shares, $776.87M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.33K sh · $56,707
Officer · 3.33K sh · $56,690
Officer · 6.66K sh · $113,397
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology